Bioinspired nanozyme-exoskeletonized yeast-derived polysaccharides for treating comorbid anxiety and depression in inflammatory bowel disease.
Nature communications · 2026
Abstract originale
Inflammatory bowel disease (IBD) is a chronic condition frequently accompanied by psychological comorbidities, such as anxiety and depression. Although current treatments may alleviate some of these symptoms, the intricate pathogenesis of these comorbidities highlights an urgent need for therapeutic strategies with combined anti-inflammatory, barrier-reparative, and microbiota-modulating effects. Herein, we develop a series of nanozyme-exoskeletonized yeast-derived polysaccharides (NZEP) by integrating nanozymes with yeast-derived polysaccharides using an insect sclerotization-inspired strategy. Among them, NZEPTA-Ce, with the highest degree of nanozyme-exoskeletonization, is capable of disrupting the inflammatory vicious cycle by inhibiting MAPK and NF-κB-mediated inflammatory signaling pathways. Oral administration of NZEPTA-Ce in mice enables effective retention and accumulation in inflamed colonic regions, reverses the homeostasis imbalance of intestinal inflammation and promotes intestinal barrier repair. Furthermore, NZEPTA-Ce treatment reverses gut microbiota dysbiosis and optimizes the composition of microbial metabolites, thereby alleviating anxiety and depressive symptoms associated with IBD. This study provides a safe and promising therapeutic strategy for the management of IBD patients and their associated psychological comorbidities.
Parole chiave
Leggi il testo integrale originale
Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.
Bioinspired nanozyme-exoskeletonized yeast-derived polysaccharides for treating comorbid anxiety and depression in inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic condition frequently accompanied by psychological comorbidities, such as anxiety and depression. Although current treatments may alleviate some of these symptoms, the intricate pathogenesis of these comorbidities highlights an urgent need for therapeutic strategies with combined anti-inflammatory, barrier-reparative, and microbiota-modulating effects. Herein, we develop a series of nanozyme-exoskeletonized yeast-derived polysaccharides (NZEP) by integrating nanozymes with yeast-derived polysaccharides using an insect sclerotization-inspired strategy. Among them, NZEPTA-Ce, with the highest degree of nanozyme-exoskeletonization, is capable of disrupting the inflammatory vicious cycle by inhibiting MAPK and NF-κB-mediated inflammatory signaling pathways. Oral administration of NZEPTA-Ce in mice enables effective retention and accumulation in inflamed colonic regions, reverses the homeostasis imbalance of intestinal inflammation and promotes intestinal barrier repair. Furthermore, NZEPTA-Ce treatment reverses gut microbiota dysbiosis and optimizes the composition of microbial metabolites, thereby alleviating anxiety and depressive symptoms associated with IBD. This study provides a safe and promising therapeutic strategy for the management of IBD patients and their associated psychological comorbidities.
The treatment of comorbid anxiety and depression in inflammatory bowel disease (IBD) is challenging. Here, the authors develop a bioinspired nanozyme-exoskeletonized yeast polysaccharide that targets intestinal inflammation, scavenges reactive oxygen species, restores immune and microbial homeostasis, repairs the intestinal barrier, and alleviates anxiety- and depression-like behaviors in IBD models.
Introduction
Inflammatory bowel disease (IBD) is a chronic, relapsing immune-mediated disorder primarily affecting the ileum, rectum, and colon, with Crohn’s disease and ulcerative colitis being its main subtypes1,2. Patients are typically diagnosed in early adulthood, but chronic inflammation persists throughout life. The global burden of IBD remains a persistent health issue. The impact of IBD extends beyond the gastrointestinal tract, as patients often experience psychological comorbidities, such as anxiety and depression3. IBD patients are at an increased risk of developing depression and anxiety compared to the general population, with up to one-third of IBD patients experiencing anxiety symptoms and one-fourth experiencing depressive symptoms4. Comorbid anxiety and depression in IBD can significantly reduce patients’ quality of life, complicate clinical management, and increase the frequency of active disease5,6. Recent studies have found that IBD patients experience a reduction in depression and anxiety symptoms following treatment with TNF inhibitors or antidepressants7,8. However, it remains unclear whether this effect is directly related to the improvement in IBD activity. Given the complex pathogenesis of comorbid anxiety and depression in IBD, research and treatment in this field face numerous challenges. Therefore, there is an urgent need to develop new therapeutic and intervention strategies.
Recent research highlights that the mechanisms underlying comorbid anxiety and depression in IBD are primarily centered on the gut-brain axis, a complex network that governs bidirectional communication between the gut and the brain. One characteristic of IBD is the disruption of inflammatory homeostasis within the gut environment, often accompanied by an impaired gut vascular barrier. This impairment allows inflammatory mediators and pathogen-associated molecular patterns, such as lipopolysaccharides (LPS), to enter the systemic circulation and reach the brain, potentially leading to the closure of the choroid plexus and the manifestation of abnormal anxiety-like behaviors9. Furthermore, inflammatory mediators in the systemic circulation may breach the blood-brain barrier, infiltrating critical brain regions such as the hippocampus, thereby contributing to the progression of psychiatric disorders10. Additionally, the gut microbiota exerts a significant influence on brain physiological functions via the gut-brain axis11,12. Dysbiosis of the gut microbiota, a common feature in IBD patients, is characterized by alterations in microbial diversity resulting from a disrupted microbiota balance and corresponding functional changes. Numerous studies have demonstrated a strong association between gut microbiota dysbiosis and severe psychiatric disorders, including depression, anxiety, and psychosis13. Consequently, reversing intestinal inflammation, repairing the intestinal barrier, and restoring microbial balance are critical approaches for addressing comorbid anxiety and depression in IBD patients.
Yeast-derived polysaccharides (such as yeast glucan particles, YGPs) possess immunomodulatory functions and are widely used as therapeutic agents to activate or suppress the immune system14,15. β-glucan and chitin are common polysaccharides found in the fungal cell wall. Upon binding with β-glucan, immune cells exhibit enhanced activity of intracellular antioxidant enzymes, such as catalase (CAT) and superoxide dismutase (SOD), which bolsters their capacity to scavenge reactive oxygen species (ROS), thereby mitigating ROS-induced tissue damage16,17. Additionally, fungal mannan in the fungal cell wall can activate mannose receptors (MR/CD206) on M0 immune cells, leading to their transformation into M2 phenotype macrophages and upregulation of IL-4-related cytokines, producing an anti-inflammatory effect18. Moreover, YGPs, as a prebiotic, could selectively enhance the growth of beneficial gut bacteria (Bacteroides) and contribute to the regulation of the gut microbiome19,20. Based on these functions, YGPs may serve as a potential candidate for combating comorbid anxiety and depression in IBD patients. However, during active inflammation of IBD, the enhancement of antioxidant enzyme activity in immune cells by YGPs is not sufficient to reverse the homeostasis imbalance of intestinal inflammation. In recent years, the emerging field of nanozymes has shown promise in efficiently and rapidly scavenging ROS at inflammation sites by mimicking the activity of natural enzymes21,22. Nanozymes have already been applied in the treatment of various inflammation-related diseases23,24. Therefore, we hypothesized that combining nanozymes with YGPs could synergize the inherent advantages of both biomaterials, effectively reversing the inflammatory environment and microbial dysbiosis, ultimately achieving the treatment of comorbid anxiety and depression in IBD.
In this study, we propose an insect sclerotization-inspired strategy to integrate nanozymes with YGPs, constructing nanozyme-exoskeletonized yeast-derived polysaccharides (NZEP) for the treatment of comorbid anxiety and depression in IBD.
NZEP exhibits a superior ability to disrupt the inflammatory vicious cycle by inhibiting mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB)-mediated inflammatory signaling pathways. The orally administered NZEP could effectively retain and accumulate in inflamed regions of the intestine, reversing the IBD-induced homeostasis imbalance of intestinal inflammation and promoting intestinal barrier repair. Furthermore, NZEP could regulate the abundance and diversity of gut microbiota, reverse microbial dysbiosis, and optimize the composition of microbial metabolites, thereby alleviating anxiety and depressive symptoms associated with IBD (Fig. 1). This work presents a promising therapeutic approach for modulating the microbiota-gut-brain axis in IBD and patients with related psychological comorbidities.
Results
Synthesis and characterization of nanozyme-exoskeletonized yeast-derived polysaccharides
Purification of YGPs with a diameter of approximately 4.060 μm is achieved from S. cerevisiae using acid and alkaline extraction methods to remove intracellular and cell wall polysaccharides (Supplementary Fig. 1a–c)25. The purified YGPs were validated through transmission electron microscopy (TEM) to confirm their hollow structure and intact rigid skeletal framework. Furthermore, energy dispersive spectroscopy (EDS) element mapping confirms that the YGPs are composed of β-glucan and chitin (the N element is attributed to chitin) (Supplementary Fig. 1d). During the strong alkaline treatment stage in the purification process, chitin undergoes deacetylation to transform into chitosan. Characterization of the YGPs through X-ray photoelectron spectroscopy (XPS) revealed the presence of -NH2 signal peaks (399.2 eV) in the high-resolution N1s XPS spectrum, confirming the progress of the deacetylation reaction (Fig. 2a). The presence of -NH2 groups on the surface of YGPs inspired us to develop a method for NZEP employing an insect sclerotization-inspired strategy (phenol oxidases-assisted phenol-polyamine chemistry). To confirm if the -NH2 on YGPs surfaces can crosslink with polyphenols (tannic acid (TA), epigallocatechin gallate (EGCG), gallic acid (GA), caffeic acid (CA), Ellagic acid (EA)) through a phenol-amine chemical reaction (Fig. 2b), we selected glucosamine (Gluc) and GA as model molecules for validation (Fig. 2c). Under alkaline conditions, catechol hydroxyl groups are oxidized by oxygen to form quinone structures. Subsequently, they react with amino groups through nucleophilic addition (Schiff base or Michael addition) reactions (Supplementary Fig. 2a)26,27. We verified the nucleophilic addition products through hydrogen nuclear magnetic resonance (1H NMR) spectroscopy (Supplementary Fig. 2b). Compared to the 1H NMR spectrum of quinone, the reaction mixture exhibits the emergence of two new sets of peaks (H1 and H2, H3 and H4) with reduced peak signals (Hb, Hc), suggesting the simultaneous occurrence of Michael addition and Schiff base reactions throughout the reaction process. Then, the chemical structures of these nucleophilic addition products were further confirmed by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (MS), and MALDI-TOF/MS spectrometry data analysis revealed the presence of molecular ion peaks corresponding to both Schiff base (Glu-Sb-GA) and Michael addition (Glu-Ma-GA) reaction products in the resulting compounds (Fig. 2d).
Based on the mechanism described above, we developed a one-step biomimetic modification strategy for constructing NZEP. Polyphenol and Ce (NO3)3 were selected as raw materials to construct the nanozyme-exoskeleton. Firstly, the as-prepared NZEP were evaluated by dynamic light scattering (DLS). The hydrodynamic diameters of these NZEP ranges from 4.469 to 6.522 μm, with a negatively charged surface (Fig. 2e and Supplementary Fig. 3). Upon comparison, it was found that the NZEP constructed by TA (NZEPTA-Ce) exhibited the largest hydrodynamic diameter, suggesting a higher degree of nanozyme-exoskeletonization by TA. To further quantitatively characterize the degree of nanozyme-exoskeletonization on NZEP, the NZEP was characterized using XPS (Fig. 2f). By comparing the atomic percentages of cerium elements (Ce), it was observed that, apart from EA, the atomic percentage of cerium elements is positively correlated with the number of polyphenol groups. Also, the thermogravimetric analysis (TGA) of those NZEP were measured in ambient air, the residual masses of NZEPTA-Ce and NZEP formed by EGCG (NZEPEGCG-Ce) were measured to be 13.86% and 10.61%, respectively. The residual masses of NZEP formed by GA (NZEPGA-Ce) and CA (NZEPCA-Ce) were measured to be 9.50% and 7.57%, respectively. This could be attributed to the lower number of phenolic hydroxyl groups, leading to a reduced degree of nanozyme-exoskeletonization (Fig. 2g). It is worth noting that, despite EA having a higher number of phenolic hydroxyl groups in its chemical structure, it cannot effectively achieve the nanozyme-exoskeletonization process on YGPs. This result may be attributed to its strong intramolecular hydrogen bonding and poor water solubility. Further observation of the morphology of NZEP through TEM reveals that the surface of YGPs is covered with a coating formed by MPN-Ce, with the morphology remaining essentially unchanged (Fig. 2h). Additionally, by utilizing EDS elemental mapping (Supplementary Fig. 4) and high-angle annular dark-field (HAADF) imaging to determine the cerium element, further intuitively verified the above phenomenon.
In an alkaline environment, through nucleophilic addition and in situ hydrolysis processes28,29 (Supplementary Fig. 5a), TA-Ce could be effectively loaded onto the surface of the YGPs. To assess the specificity of the exoskeletonization process mediated by TA and Ce3+, we investigated the role of different metal ions. Ce3+, Zn2+, Pd2+, Mn2+, Cu2+, and Fe2+ were individually used as metal ion sources to synthesize NZEP with different TA-metal exoskeletonized structures (NZEPTA-M) using the same preparation method. TEM and EDS mapping analyses of the metal distribution and content on the NZEP surface demonstrated that, apart from NZEPTA-Ce, other NZEPTA-M variants exhibited minimal metal incorporation (Supplementary Fig. 5b). DLS analysis showed that, with the exception of NZEPTA-Ce, the other NZEPTA-M formulations did not display significant differences from bare YGPs (Supplementary Fig. 5c, d). This indicated that under alkaline conditions, Zn2+, Pd2+, Mn2+, Cu2+, and Fe2+ failed to deposit onto the YGPs surface via in situ hydrolysis. Under alkaline conditions, the -NH₂ groups on YGPs interact with polyphenols like TA to form a stable network, while TA’s hydroxyl groups oxidize, complex with Ce3+, and undergo in situ hydrolysis, collectively leading to the formation of TA-Ce. Two interlinked processes together facilitated the formation of the tannic acid-cerium nanozyme exoskeleton (NZEPTA-Ce). These findings demonstrated that NZEPTA-Ce exhibits distinct exoskeletonization characteristics. The well-defined exoskeleton cannot be easily replicated by substituting TA with other polyphenols or Ce3+ with different metal ions, underscoring the specificity of the TA-Ce interaction in establishing a stable nanozyme exoskeleton.
Of note, there was a higher enrichment of MPN-Ce at the budding sites, and compared to other polyphenols, NZEP constructed with TA exhibited greater enrichment of TA-Ce at the budding sites (Fig. 2h and Supplementary Fig. 6a). This is likely due to a higher chitosan content at the budding sites compared to other locations30. The surface chemical composition and valence states of NZEPTA-Ce were further evaluated by XPS (Supplementary Fig. 6b, c). Among them, the proportions of C, O, N, and Ce elements in NZEPTA-Ce were 57.56%, 39.84%, 1.15%, and 1.46%, respectively. The ratio of tri- to tetravalent cerium (Ce3+/Ce4+) was 55.6%:44.4%, indicating that the cerium oxide in the NZEPTA-Ce could act as a superoxide dismutase to eliminate intracellular superoxide and free radicals, playing an antioxidative role31. To elucidate the distribution of Ce within NZEPTA-Ce, cross-sectional TEM and HAADF imaging were conducted. The analyses revealed that TA-Ce is predominantly confined to the surface of NZEPTA-Ce, with minimal presence in the interior, supporting the proposed exoskeletal structural model (Supplementary Fig. 6d). TEM images showed the TA-Ce had a nanoparticle morphology, with C, O, and Ce elements evenly distributed. It tends to aggregate into irregular amorphous structures, which contrasts sharply with the distinct individual particle morphology of NZEPTA-Ce (Supplementary Fig. 7). To further quantify the nanozyme-exoskeleton in NZEPTA-Ce, TGA analysis revealed that TA-Ce constituted approximately 41.56% of NZEPTA-Ce, while the remaining 58.44% was composed of YGPs (Supplementary Fig. 8). NZEPTA-Ce exhibited excellent stability in simulated gastrointestinal (GI) fluids, with no significant changes in particle size, nanozyme activity, or morphology, confirming its ability to maintain the integrity of the TA-Ce exoskeleton and exert ROS-scavenging effects at inflamed intestinal sites (Supplementary Fig. 9). We have found that TA-Ce was similarly stable in gastric fluid, retaining its morphology, elemental distribution, and enzymatic activity to ensure sustained ROS scavenging once it reaches the intestine. (Supplementary Fig. 10).
Antioxidant and macrophage cellular targeting capabilities of NZEPTA-Ce
The prominent characteristic of MPN-Ce as the exoskeleton of YGPs lies in its ability to confer potent capabilities to yeast-derived polysaccharides in combating oxidative stress environments. To verify the antioxidant capacity of NZEP, we selected NZEPTA-Ce with the highest exoskeletonization degree for the experiment. It was utilized in classical 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonate) (ABTS) radical scavenging assays. As depicted in Fig. 3a, b, treatment with 150 μg/mL NZEPTA-Ce resulted in the removal of approximately 40% of DPPH radicals and 80% of ABTS radicals. Furthermore, selecting three representative biologically relevant reactive oxygen species (ROS), H2O2, ·O2−, and ·OH, to investigate the ROS scavenging activity of NZEPTA-Ce. The NZEPTA-Ce demonstrates significant ROS scavenging activity, exhibiting concentration-dependent behavior. Approximately 50% of ·OH were eliminated by 150 μg/mL of NZEPTA-Ce (Fig. 3c). Treatment with 150 μg/mL of the NZEPTA-Ce resulted in the decomposition of approximately 60% of ·O2−, demonstrating the SOD-like activity of NZEPTA-Ce (Fig. 3d). Moreover, at a concentration of 150 μg/mL, close to 90% of H2O2 was effectively cleared indicating that the NZEPTA-Ce also possesses CAT-like activity (Fig. 3e). The experimental results above confirm that the TA-Ce as the exoskeleton on the surface of NZEPTA-Ce exhibits potent antioxidant capabilities, capable of eliminating various ROS through the change in cerium oxidation states (Fig. 3f).
It is widely recognized that the β-1,3-D-glucan on the surface of YGPs is classified as a pathogen-associated molecular pattern, capable of being recognized by pathogen recognition receptors on host immune cells, such as Dectin-1, complement receptor 3 (CR3), and TLR2, thereby targeting phagocytes like macrophages. We hypothesize that the NZEPTA-Ce also possesses macrophage-targeting capabilities. The biocompatibility of the NZEPTA-Ce with cells was first evaluated. At concentrations below 150 μg/mL, the NZEPTA-Ce had minimal impact on cell viability. Furthermore, the NZEPTA-Ce and its components showed no significant toxicity to Mouse mononuclear macrophage leukemia (RAW 264.7) cells and human colorectal adenocarcinoma (Caco2) cells at this concentration (Supplementary Fig. 11). To investigate the NZEPTA-Ce’s high specificity and affinity for macrophages, FITC fluorescent probes were labeled on the NZEPTA-Ce, and the NZEPTA-Ce uptake assays were conducted in the RAW 264.7 macrophage and Caco2 cell line. NZEPTA-Ce were internalized into the cytoplasm of RAW 264.7 cells, while almost no internalization of NZEPTA-Ce was observed in Caco2 cells within 12 h (Fig. 3g). It is noteworthy that, to further simulate the cellular status under inflammatory conditions, the RAW 264.7 and Caco2 cells were stimulated with LPS, followed by another round of NZEPTA-Ce cellular uptake experiments. The experimental results revealed that after LPS stimulation, RAW 264.7 cells underwent polarization, leading to a significant enhancement in the internalization efficiency of NZEPTA-Ce. By co-localization analysis experiments, it was further verified that NZEPTA-Ce was effectively internalized into the cell interior rather than simply attached to the cell membrane surface (Supplementary Figs. 12 and 13). In contrast, the Caco2 cells still could not uptake or internalize the NZEPTA-Ce (Fig. 3h). To further investigate the targeting mechanism of NZEPTA-Ce for macrophages, we first confirmed the expression of Dectin-1, TLR2 and CR3 on the membrane of RAW264.7 cells (Supplementary Fig. 14). Receptor neutralization with specific antibodies significantly inhibited NZEPTA-Ce uptake, reducing internalization from ~4.24% to ~0.15%, with a more pronounced effect in LPS-stimulated cells (Supplementary Fig. 15). These results demonstrate that NZEPTA-Ce was primarily internalized by macrophages through receptor-mediated endocytosis involving Dectin-1, CR3, and TLR2. The above results demonstrate that NZEPTA-Ce’s robust antioxidant properties and its selective targeting of macrophages at the site of inflammation could potentially provide a targeted therapeutic approach for intestinal inflammation.
Antioxidant and anti-inflammatory properties of NZEPTA-Ce in vitro
Excessive ROS-induced intestinal oxidative stress is considered a major factor in the onset and progression of IBD32. Therefore, we first investigated the antioxidant activity of NZEPTA-Ce on immune cells under oxidative stress conditions. tert-Butyl Hydroperoxide (tBHP) is one of the most important biologically relevant ROS due to its strong membrane permeability and longer half-life compared to O2− and ·OH33. Hence, the co-cultivation of tBHP with RAW 264.7 was utilized to mimic the physiological environment of IBD, while assessing the intracellular oxidative stress status through DCFH-DA (a probe that fluoresces green in the presence of ROS) analysis. RAW 264.7 treated with tBHP displayed intense green fluorescence within the cells, indicative of elevated intracellular oxidative stress levels (Fig. 4a). Subsequent treatment with YGPs resulted in a reduction of green fluorescence in certain cells. Conversely, treatment with TA-Ce and NZEPTA-Ce led to a notable absence of green fluorescence within the cells (Fig. 4b). Further quantitative analysis of intracellular oxidative stress levels was conducted through flow cytometry, revealing the mild mitigating effect of YGPs on reducing intracellular oxidative stress levels. TA-Ce and NZEPTA-Ce were able to significantly alleviate intracellular oxidative stress levels (Fig. 4c).
Intense inflammatory disruption is a prominent feature of IBD34,35. Yeast-derived polysaccharides possess immunomodulatory functions and are widely used as therapeutic agents to either activate or suppress the immune system15. In particular, the treatment of macrophages with LPS and IFN-γ allowed for a detailed investigation into the influence of the NZEPTA-Ce on the polarization process of macrophages. Confocal laser scanning microscopy images and flow cytometry analysis (Fig. 4d–f and Supplementary Fig. 16a) revealed that LPS + IFN-γ-induced macrophages showed an upregulation of the M1 macrophage marker (CD86) and a downregulation of the M2 macrophage marker (CD206), with YGPs showing a slight reversal of these alterations. As TA-Ce lacks the capacity to modulate immune cell polarization, it primarily reduced the expression of M1 markers, with a less pronounced increase in M2 markers. Remarkably, post- NZEPTA-Ce treatment, there was a significant reduction in the expression of the M1 macrophage marker (CD86) and a marked increase in the expression of the M2 macrophage marker (CD206). Additionally, Real-time reverse transcription polymerase chain reaction (RT-qPCR) analysis revealed a significant upregulation of pro-inflammatory mRNA expressions (TNF-α, IL-1β, iNOS, and CD86) after LPS + IFN-γ stimulation, while treatment with the NZEPTA-Ce markedly downregulated their mRNA expression level (Supplementary Fig. 16b). Compared to YGPs, NZEPTA-Ce demonstrates significantly enhanced anti-inflammatory effects, possibly attributed to the dual functionality of NZEPTA-Ce, which includes the ROS scavenging capability of the nanozyme-exoskeleton and the immunomodulatory role of YGPs. The synergistic effect of these properties in NZEPTA-Ce allows for the disruption of the vicious cycle of inflammation, presenting potent anti-inflammatory efficacy and showing significant potential to restore the homeostatic balance of intestinal inflammation (Fig. 4g).
To further simulate the physiological environment of immune cells and Caco2 cell under conditions of disrupted intestinal inflammatory homeostasis, we established an in vitro model by simultaneously adding LPS, IFN-γ, and tBHP to the culture medium, and utilized live/dead staining to assess the NZEPTA-Ce’s synergistic protective effect. The environment of inflammation severely impairs the viability of RAW 264.7 and Caco2 cell, with a significant increase in the red fluorescence of PI compared to the normal culture environment (Fig. 4h and Supplementary Fig. 17). While the individual effects of immunomodulatory or antioxidant activity may slightly alleviate the cytotoxicity induced by the vicious cycle of inflammation, the NZEPTA-Ce completely interrupts the process of the vicious cycle of inflammation, significantly enhancing cell viability. Cell viability is nearly 100%, with no apparent red fluorescence of PI, indicating a pronounced cell-protective effect.
Potential anti-inflammatory mechanism via RNA-sequencing analysis
The NZEPTA-Ce’s strong antioxidant and anti-inflammatory effects in the experiment prompted us to explore its potential mechanisms further. RAW 264.7 cells were initially stimulated with LPS, IFN-γ, and tBHP (model group) and then treated with NZEPTA-Ce (NZEPTA-Ce group). The differentially expressed genes (DEGs) between the two groups were then identified and analyzed. RAW 264.7 cells treated with NZEPTA-Ce exhibited a significant increase in 1321 DEGs compared to the model group, including Il-11 and Tgfb3, which encode anti-inflammatory cytokines, and Fem1a, linked to PGE2-EP4-mediated macrophage inflammation suppression36,37. Moreover, 1384 DEGs were significantly downregulated, including inflammatory markers like Il6, Il1a, and Tnf
38–40 (Fig. 5a). The heat map of DEGs revealed that the upregulated DEGs were primarily associated with inhibiting inflammatory responses, reducing cellular oxidative stress, promoting cell proliferation, and immune regulation. In contrast, the downregulated DEGs were mainly involved in promoting inflammatory responses and inducing cellular oxidative stress (Fig. 5b). We conducted gene ontology (GO) enrichment analysis on DEGs using biological processes, cellular components, and molecular functions. The analysis showed that NZEPTA-Ce significantly affected inflammation-related processes, particularly cytokine signaling pathways and chemokine production regulation, and modulated cytokine activity and their receptors, indicating a wide impact on immune functions (Fig. 5c). Grouping the differentially expressed genes for KEGG enrichment analysis revealed potential molecular mechanisms, including cytokine interactions, IBD, and the intestinal immune network for IgA production (Supplementary Fig. 18). This indicates that NZEPTA-Ce may have therapeutic potential for IBD and related inflammatory diseases. We performed gene set enrichment analysis (GSEA) to examine the enrichment of differentially expressed genes in biological pathways. This revealed several significantly enriched pathways, mainly associated with cellular inflammation and oxidative stress, including the Toll-like receptor (TLRs, NES = − 1.95), mitogen-activated protein kinase (MAPK, NES = − 1.61), and nuclear factor-κB (NF-κB, NES = − 0.50) signaling pathways. These findings indicate that NZEPTA-Ce plays a crucial role in inhibiting cellular inflammation and maintaining oxidative stress homeostasis (Fig. 5d). Finally, we validated the mRNA and protein expression of key differentially expressed genes (Il-1a, Il-1b, Il-6, Nos2, Tnfa, Il-4, Il-11, Tgfb3, Fem1a, and Akap1) through RT-qPCR and cellular immunofluorescence experiments (Supplementary Fig. 19). The results were consistent with the RNA-sequencing data. Based on the comprehensive results from the above experiments, the potent anti-inflammatory mechanisms of the NZEPTA-Ce can be hypothesized as follows (Fig. 5e). The NZEPTA-Ce scavenges both exogenous and endogenous ROS (produced via the Toll-like receptor signaling pathway), blocking the MAPK and NF-κB-mediated inflammatory signaling pathways. This disruption breaks the vicious cycle of inflammation, inhibits the polarization of M1 phenotype immune cells, reduces the secretion of pro-inflammatory cytokines, and alleviates the inflammatory response.
Retention and targeting processes of NZEPTA-Ce in colonic inflammation
Prolonged retention and targeting at the site of colonic inflammation are advantageous for enhancing the effectiveness of oral therapy and reducing potential toxic side effects41. Hence, we investigated the distribution and retention of the NZEPTA-Ce in both DSS-induced IBD and normal C57BL/6 mice models. NZEPTA-Ce modified with Cyanine 5.5 (Cy5.5) were orally administered in DSS- induced IBD and normal mice (Fig. 6a). The fluorescence intensity of NZEPTA-Ce in the abdominal cavities of different mice was monitored at 6, 12, 18, and 24 h using an in vivo imaging system (Fig. 6b). The fluorescence intensity of NZEPTA-Ce in the abdominal cavity of DSS induced IBD mice at 6, 12, 18, and 24 h after oral administration was 2.28, 2.13, 2.96, and 3.0 times higher than that of the normal group, indicating that NZEPTA-Ce has a prolonged retention effect in the inflamed intestine (Fig. 6c, d). To further elucidate the targeted and retention effects of NZEPTA-Ce on the inflamed colonic region, the aforementioned experimental procedure was repeated. Following oral administration of NZEPTA-Ce at 6, 12, 18, and 24 h, the gastrointestinal tract was excised for ex vivo fluorescence imaging. Subsequently, the fluorescence distribution of collected ex vivo tissues was analyzed and statistically evaluated (Fig. 6e). During the experimental observation period, the distribution of NZEPTA-Ce in the stomach remained consistent between the normal group and the DSS group, showing no significant differences (Fig. 6f). Following oral administration at 12 and 18 h, the fluorescence intensity in the colon of the DSS group was 3.36 and 2.78 times higher than that in the normal group, respectively. Even at 24 h, the colon of the DSS group continued to exhibit strong fluorescence emission (Fig. 6g). Fluorescence staining of colon tissue sections from the DSS group after treated with NZEPTA-Ce demonstrated the presence of NZEPTA-Ce accumulation on the surface of the colonic region (Supplementary Fig. 20a). These results indicate that NZEPTA-Ce can more effectively target and accumulate in the inflamed colonic regions. In addition, no strong fluorescence accumulation was observed in the hearts, livers, spleens, lungs, and kidneys of the two groups of mice during the treatment process (Supplementary Fig. 20b).
Before assessing the therapeutic efficacy of NZEPTA-Ce for IBD, we evaluated the in vivo biocompatibility through oral administration. No significant weight loss or organ differences were noted compared to the control group during the treatment (Supplementary Fig. 21). Key blood parameters, including white blood cells, red blood cells (RBC), monocytes (MON), platelets (PLT), and others, remained within normal ranges. Liver function indicators, including alanine aminotransferase (ALT), albumin (ALB), aspartate aminotransferase (AST), and total protein (TP), showed no significant changes (Supplementary Fig. 22). Furthermore, to investigate any potential damage to major organs during oral treatment with the NZEPTA-Ce, ex vivo organs were subjected to hematoxylin and eosin (H&E) staining at the end of the experiment. No significant pathological changes were observed in the histological analysis (Supplementary Fig. 23), and NZEPTA-Ce exhibited negligible hemolysis of RBC up to a concentration of 1200 μg/mL (Supplementary Fig. 24). These experimental results suggest that NZEPTA-Ce does not cause systemic toxicity when taken orally.
Therapeutic effect of NZEPTA-Ce in DSS-induced IBD mice model
The remarkable anti-inflammatory effects of NZEPTA-Ce in vitro, along with its specific targeting of inflamed colonic regions, prompted us to investigate its therapeutic potential in restoring intestinal inflammatory balance in a DSS-induced IBD model in C57BL/6 mice. The mice received 3% DSS in drinking water orally for 7 days consecutively to induce IBD. Following this, they were randomly assigned to five groups: normal, model, YGPs, TA-Ce, and NZEPTA-Ce. The model group, acting as the positive control, remained untreated, while the other groups received the respective treatments via oral gavage for 5 days (Fig. 7a). Throughout the treatment, body weight monitoring showed that mice treated with YGPs or TA-Ce experienced less weight loss compared to the model group, indicating a mitigating effect of YGPs or TA-Ce on IBD. Mice treated with NZEPTA-Ce not only showed greater body weight recovery compared to other groups but also displayed a progressive increase during treatment (Fig. 7b). Compared to the model group, NZEPTA-Ce significantly alleviated IBD symptoms, as reflected by the disease activity index (DAI) and anal blood residue (Fig. 7c, d).
In IBD, inflammation and extracellular matrix buildup are usually limited to the colonic mucosa and submucosa, causing the mucosal muscle layer to thicken, potentially shortening or stiffening the colon and impairing motility42. Colon length in the model group decreased by 41.6% compared to the normal group, while mice treated with NZEPTA-Ce showed only a 10% reduction (Fig. 7e, f, and Supplementary Fig. 25). Transverse colon sections were prepared and examined for histopathological changes using H&E staining (Fig. 8a). The model group showed severe colonic crypt disruption, high immune cell infiltration, and significant epithelial damage. In contrast, NZEPTA-Ce treated mice displayed mostly normal colon microstructure and reduced inflammatory cell infiltration (Fig. 8b). The quantitative evaluation of histopathological scores confirmed that NZEPTA-Ce effectively reduced inflammation at colonic lesions. The NZEPTA-Ce group had significantly lower histological scores than the model group, indicating reduced inflammation and crypt damage (Fig. 8c). To further characterize inflammatory and barrier-associated changes in colonic tissues after treatment, macrophage-associated markers, inflammatory and oxidative stress indices, and tight junction proteins were examined. Quantitative analysis showed numerically lower CD86 fluorescence intensity and higher CD206 fluorescence intensity in the NZEPTA-Ce group than in the model group (Fig. 8d and Supplementary Fig. 26). Similarly, MPO activity and MDA content were numerically lower in the NZEPTA-Ce group than in the model group, whereas the fluorescence intensities of ZO-1 and occludin were numerically higher. (Supplementary Figs. 27 and 28). Furthermore, no accumulation of Ce ions was detected in the blood of mice, indicating that NZEPTA-Ce did not lead to Ce ion retention in the body at the dosage used for IBD treatment (Supplementary Table 5).
Effects of NZEPTA-Ce on gut microbiota and microbial metabolites
Gut microbiome imbalance is key in IBD development. Recent studies reveal that gut microbiota influences the immune, metabolic, and nervous systems via the “gut-brain axis.”11,43 To study NZEPTA-Ce’s effects on gut microbiota and metabolism in IBD-treated mice, we collected fecal samples from healthy and IBD mice treated with YGPs, TA-Ce, or NZEPTA-Ce for 16S ribosomal RNA (rRNA) gene sequencing. The α-diversity analysis showed a significant reduction in microbiome diversity and abundance in the feces of DSS-induced IBD mice (Supplementary Fig. 29a, b). In contrast, the NZEPTA-Ce group exhibited gut microbiota abundance and diversity comparable to the normal group, suggesting that the treatment may have restored these metrics in the mice. β-diversity shows species quantity and distribution differences within communities. The unweighted UniFrac distance matrix heatmap revealed significant differences between the NZEPTA-Ce group, healthy mice, and the model group (Supplementary Fig. 29c). Family-level analysis showed that the NZEPTA-Ce group had more beneficial bacteria like Muribaculaceae, Prevotellaceae, Rikenellaceae, and Clostridia-UCG-014. Clinical data indicate that Muribaculaceae exhibits a higher relative abundance in healthy individuals compared to those with IBD44. Furthermore, Prevotellaceae is recognized for its production of short-chain fatty acids (SCFAs)45. In contrast, the NZEPTA-Ce group demonstrated a significant reduction in the abundance of pathogenic bacteria, such as Enterobacteriaceae and Tannerellaceae, which are associated with the exacerbation of IBD (Fig. 9a). Cluster analysis conducted at the species level indicated that the NZEPTA-Ce treatment significantly increased the abundance of anti-inflammatory bacteria, including Faecalibacterium prausnitzii_(g_Faecalibacterium) and Alistipes_sp._(g_Alistipes)46,47. The treatment increased the abundance of SCFA-synthesizing bacteria, including uncultured bacterium g_Muribaculaceae, Clostridiales bacterium g_Lachnospiraceae NK4A136 group, uncultured bacterium g_Prevotellaceae UCG-001, and uncultured bacterium g_Roseburia, while significantly reducing harmful bacteria like Escherichia coli (g_Escherichia-Shigella) and Streptomyces sp. (g_Escherichia-Shigella) (Fig. 9b, c). NZEPTA-Ce efficiently eliminates ROS from IBD lesions, while mannose encourages the growth of probiotics, potentially explaining the increased relative abundance of probiotics. The KEGG Orthology (KO) heatmap indicates that the NZEPTA-Ce group resembled the healthy group more than the model group, particularly in metabolic functions, organismal systems, and human diseases. At the second KEGG level, NZEPTA-Ce improved immune functions and environmental adaptability, as well as enhanced lipid, carbohydrate, and amino acid metabolism in IBD mice (Fig. 9d). Experimental results show that NZEPTA-Ce treatment reverses gut microbiota dysbiosis, aiding gut immunity regulation and intestinal tissue repair.
The Linear discriminant analysis Effect Size (LEfSe) analysis showed a significant increase in Eubacterium abundance in the NZEPTA-Ce group compared to the model group. This bacterium’s depletion is linked to major depressive disorder (MDD)48,49. Changes in gut microbiota composition affect the microbial metabolome, significantly influencing the development of MDD13. We analyzed metabolite changes in different mouse groups using untargeted metabolomics. Principal component analysis (PCA) revealed significant differences in metabolite distributions among the normal, model, and NZEPTA-Ce groups (Supplementary Fig. 30a, b). We analyzed metabolite differences among the three groups. The model group showed 1718 upregulated and 1472 downregulated metabolites compared to the normal group. In contrast, the NZEPTA-Ce group had 672 upregulated and 679 downregulated metabolites, suggesting its metabolite profile was more similar to healthy mice (Supplementary Fig. 30c). Additionally, the NZEPTA-Ce group had 1367 upregulated and 1024 downregulated metabolites compared to the model group (Supplementary Fig. 30d).
We discovered that IBD mice experienced changes in some endogenous metabolite levels after YGPs intervention by comparing the differential metabolites in the YGPs and model groups (Supplementary Fig. 31a). The NZEPTA-Ce group exhibited more significant metabolite changes than the YGPs group (Supplementary Fig. 31b). (20R,22R)-20,22-dihydroxycholesterol, a natural metabolite crucial for hormone production50, is elevated in DSS-induced IBD mice, aligning with our results. Its expression was reduced in both YGPs and NZEPTA-Ce-treated groups, with the NZEPTA-Ce group showing the most significant decrease compared to the model group. Aldosterone, a pivotal corticosteroid regulating electrolyte and fluid balance, exacerbates IBD by promoting ROS generation within the intestinal microenvironment51. Studies have also identified aldosteronism as a characteristic feature in patients with depression52,53. In our analysis, the Model group exhibited the highest Aldosterone metabolite levels, whereas the NZEPTA-Ce group showed the lowest levels, with YGPs falling in between. 9S-HOTrE, an anti-inflammatory eicosanoid, is reduced in enteritis patients compared to healthy individuals54 and has immunomodulating effects, as shown in mice and cell models55,56. Treatment in the NZEPTA-Ce group significantly increased the levels of 9S-HOTrE in metabolites and played a more pronounced role in increasing them than YGPs. Stearidonic acid, an Omega-3 PUFA, reduces cytokines, adhesion molecules, and reactive oxygen species to help prevent inflammatory disorders like IBD57,58. Our data indicate that NZEPTA-Ce significantly boosts stearidonic acid levels in IBD mice more effectively than YGPs. Additionally, stearidonic acid protects against neurotoxicity in rat hippocampal cells due to its antiapoptotic, antioxidant, and anti-inflammatory effects59. We speculated that the intervention of NZEPTA-Ce not only reduces the level of intestinal inflammation but also protects against neuronal damage caused by IBD.
We speculated that YGPs, as prebiotics, may influence endogenous metabolite synthesis and breakdown by stimulating the intestinal immune system. They also enhance metabolite production by inhibiting harmful microorganisms, promoting a healthy gut microbiota. In inflammatory conditions, NZEPTA-Ce exhibits anti-inflammatory and ROS-scavenging properties, supporting YGPs’ functions. Consequently, NZEPTA-Ce amplifies the above effects.
The clustering heatmap of differential metabolites (Fig. 9f) indicated that cortisone levels were lower in the NZEPTA-Ce group than in the model group. Cortisone, a crucial glucocorticoid in rodents that regulates stress, is often used in depression models. The model group exhibited elevated cortisol levels, which are typically high in major depressive disorder (MDD)60–62. Furthermore, cyclic GMP, linked to the nitric oxide/cyclic GMP (NO/cGMP) pathway, was significantly downregulated following NZEPTA-Ce treatment, highlighting its studied role in MDD63,64. The KEGG enrichment maps show that both YGPs and NZEPTA-Ce altered metabolite composition and metabolic structure by affecting steroid hormone synthesis and the metabolism of arachidonic and linoleic acids in DSS mice (Fig. 9g and Supplementary Fig. 31c). Furthermore, NZEPTA-Ce also impacted metabolites linked to long-term depressive activity in mice. These findings indicate that NZEPTA-Ce treatment reduces cortisone, cortisol, and GMP levels in mice, suggesting its potential to alleviate anxiety and depression in IBD.
Therapeutic effect of NZEPTA-Ce in CD4+CD45RBhi T cell transfer model
The CD4+CD45RBhi T cell transfer model, a well-established chronic IBD model, induces colitis by injecting naïve CD4+ T cells into lymphocyte-deficient hosts, closely mimicking T cell-mediated immunopathology and the characteristics of idiopathic IBD in humans. To further evaluate the adaptive immune regulatory effects of NZEPTA-Ce, we investigated its therapeutic efficacy and impact on gut immune cell populations (Supplementary Fig. 32a). NZEPTA-Ce treatment significantly alleviated IBD-associated clinical symptoms, including reduced perianal inflammation, body weight loss, and DAI scores compared to the model group (Supplementary Fig. 32b–d). Additionally, colon length measurements and histopathological analysis revealed attenuated colon shortening and preserved intestinal integrity, as confirmed by H&E staining (Supplementary Fig. 32e–g). A reduced spleen index further suggested potential mitigation of systemic inflammation (Supplementary Fig. 32h–j).
Flow cytometric analysis (Supplementary Figs. 33 and 34a–d) demonstrated that NZEPTA-Ce decreased pro-inflammatory Th1/Th17 cells while increasing anti-inflammatory Treg cells in the colonic lamina propria, suggesting enhanced immune tolerance. Furthermore, IL-7 immunofluorescence staining and Elisa revealed a downregulation of pro-inflammatory cytokines (IFN-γ, IL-17, and IL-21) and upregulation of anti-inflammatory cytokines (IL-10, TGF-β, and IL-4) (Supplementary Fig. 34e, f), indicating that NZEPTA-Ce restores the balance between pro- and anti-inflammatory immune responses.
All of the above results indicated that NZEPTA-Ce effectively ameliorated IBD progression by mitigating clinical symptoms, preserving intestinal integrity, suppressing inflammatory immune responses, and promoting immune homeostasis, underscoring its therapeutic potential for IBD treatment and clinical translation.
Modulating effects of NZEPTA-Ce on depression and anxiety in IBD mice
The NZEPTA-Ce has demonstrated potent potential in effectively reversing the inflammatory environment and microbial dysbiosis in the treatment of IBD. Additionally, 16S rRNA sequencing and metabolomics analyses suggest a potential link between NZEPTA-Ce treatment and the alleviation of depressive and anxiety-like behaviors. To further evaluate its effectiveness in alleviating comorbid anxiety and depression in IBD, we used DSS-induced IBD mice. After 5 consecutive days of NZEPTA-Ce treatment, we assessed the differences in anxiety and depressive-like behaviors between the NZEPTA-Ce group and the model group (Fig. 10a). In the open field test (OFT), significant changes were observed in the total distance traveled by mice in the NZEPTA-Ce group after treatment (Fig. 10b, c, and Supplementary Fig. 35a). Typically, longer time spent in the central area is interpreted as lower anxiety levels, while more time spent in the peripheral area indicates higher anxiety levels65. The average total time spent in the central area by the NZEPTA-Ce-treated mice was about 53.53 s, showing no significant difference compared to the normal group. In contrast, mice in the model group hardly spent any time in the central area (Fig. 10d). Conversely, mice in the model group spent up to 293.41 s in the peripheral area, whereas after NZEPTA-Ce treatment, this time was significantly reduced to 252.90 s (p < 0.05), approaching the normal group’s time of 217.98 s (Fig. 10e). In the elevated plus maze (EPM) test (Fig. 10f), mice in the model group showed reduced exploration of the open arms, indicating decreased risk-taking behavior, and also spent significantly less time in the center area. However, the NZEPTA-Ce group showed a significant increase in the time spent in the open arms and the number of crossings (Fig. 10g–i and Supplementary Figs. 35b, 36). In the Forced Swim Test (FST), the NZEPTA-Ce group exhibited a notable reduction in immobility time compared to the model group66 (Fig. 10j, k). To further elucidate the anxiolytic and antidepressant mechanisms of NZEPTA-Ce, we evaluated Il-1β, Il-6, Il-4, and Il-11 mRNA expression in the colon, blood, non-hippocampal brain regions, and hippocampus of DSS-induced IBD mice (Supplementary Fig. 37). We hypothesized that DSS-induced IBD would upregulate Il-1β and Il-6, correlating with increased neuroinflammation and synaptic dysfunction, which are linked to anxiety and depression behaviors. Elevated Il-1β disrupts neurogenesis and cognitive functions, while IL-6 dysregulation impairs serotonergic pathways and stress responses. Notably, NZEPTA-Ce treatment significantly reduced Il-1β and Il-6 while upregulating Il-4 and Il-11, which promote protective effects on neurons. This shift towards an anti-inflammatory state counteracted neuroinflammatory damage.
To further evaluate the anxiolytic and antidepressant effects of NZEPTA-Ce in mice, we examined the density of neurons in the hippocampus using immunofluorescence staining. Specifically, neuronal nuclei (NeuN), a marker for mature neurons, were combined with bromodeoxyuridine (BrdU) staining to identify newly formed neurons. Doublecortin (DCX), which encodes a microtubule-associated protein, is typically used as a marker for immature neurons. DSS administration significantly reduced the density of BrdU+/NeuN+ newly formed neurons and DCX+ immature neurons in the dentate gyrus (DG) region of the hippocampus. In contrast, NZEPTA-Ce treatment significantly increased the number of BrdU+/NeuN+ and DCX+ cells in the hippocampus (Fig. 10l, m, and Supplementary Figs. 38–43). Collectively, those results indicate that DSS-induced IBD indeed leads to anxiety and depressive symptoms in mice, and NZEPTA-Ce treatment effectively alleviated these anxiety and depressive-like behaviors.
Discussion
In summary, we successfully constructed a series of NZEPs through an insect sclerotization-inspired strategy. Among them, NZEPTA-Ce had the highest degree of nanozyme-exoskeletonization, which endows it with potent antioxidant and immunomodulatory properties. The ROS scavenging effect mediated by NZEPTA-Ce enzyme-like activity (SOD-, CAT-) inhibited macrophage polarization to the M1 phenotype, while the immunomodulated properties of NZEPTA-Ce components promoted macrophage polarization to the M2 phenotype. These properties allowed NZEPTA-Ce to effectively disrupt the inflammatory vicious cycle, demonstrating potent anti-inflammatory efficacy. RNA sequencing analysis revealed that the potential mechanism by which NZEPTA-Ce disrupted the vicious cycle of inflammation was the inhibition of NF-κB and MAPK-related inflammatory pathways. Thanks to the targeting of the NZEPTA-Ce to macrophages at the site of inflammation, the NZEPTA-Ce could be effectively retained and accumulate in the inflamed colonic regions after oral administration. These features of the NZEPTA-Ce could synergistically reverse the homeostasis imbalance of intestinal inflammation and promote the repair of the intestinal barrier. Furthermore, 16S rRNA gene sequencing and untargeted metabolomics analysis confirmed that NZEPTA-Ce treatment could achieve optimizing the diversity and composition of gut microbiota and improving metabolic functions related to neuroprotection, thereby alleviating anxiety and depressive symptoms associated with IBD. This study not only suggests an effective strategy to integrate nanozymes and yeast-derived polysaccharides but also develops a safe and encouraging therapeutic strategy for the management of IBD patients and associated psychological comorbidities.
Methods
Preparation of NZEP
Tannic acid (TA), epigallocatechin gallate (EGCG), gallic acid (GA), caffeic acid (CA), and ellagic acid (EA), zinc sulfate, palladium chloride, manganese sulfate, copper chloride, and ferrous sulfate, respectively, were used in the preparation of NZEP. As an example, the method of preparation of NZEPTA-Ce was as follows: TA solution (100 μL, 24 mM), Ce (NO3)3∙6H2O solution (600 μL, 24 mM), and 40 mg YGPs were added to 50 mL deionized water with stirring for 3 h. Then the pH of the solution was adjusted to 8.0 by adding NaOH solution (2 mol/L). Then, the reaction was allowed to proceed for 12 h. Finally, the as synthesized NZEPTA-Ce were collected by centrifugation and washed with deionized water three times. The other four NZEP were prepared in the same way.
Evaluation of the regulatory effect of NZEPTA-Ce on the cellular inflammatory state
RAW264.7 were seeded into 6- and 12-well plates severally at the density of 5 × 105 cells/well and 2 × 105 cells/well. After 24 h incubation, the cells were treated with LPS (200 ng/mL) and IFN-γ (20 ng/mL) for 12 h. Subsequently, the cells were incubated for another 12 h with the following groups:
(1) Model group (serum-free medium), (2) YGPs group (YGPs dispersed in serum-free medium at a concentration of 87 μg/mL), (3) TA-Ce group (TA-Ce dispersed in serum-free medium at a concentration of 63 μg/mL), (4) NZEPTA-Ce group (NZEPTA-Ce dispersed in serum-free medium at a concentration of 150 μg/mL). The cells without any treatment throughout were used as the normal group.
The cells seeded in 12-well plates were then used to perform cellular immunofluorescence staining experiments to detect protein expression of CD86 (M1 marker) and CD206 (M2 marker). In this experiment, cells were first fixed with 4% paraformaldehyde. After washing with PBST (PBS with 0.05% Tween 20) for three times, cell round coverslip were permeabilized and blocked with 5% BSA in PBS for 1 h at 37 °C. For immunofluorescence staining, tissue sections were incubated with primary antibody at 4 °C overnight. The cell round coverslip were incubated with the secondary antibody for 1 h at 37 °C and finally blocked with an anti-fluorescence quencher containing DAPI (Yeasen, China). Images were acquired with a CLSM (Cai Zeiss, Germany). The following primary antibodies were used: CD86 (Abclonal, 1:100), CD206 (Proteintech, 1:500). The cells in 6-well plates were de-labeled with CD86 and CD206 antibodies and then subjected to flow cytometry analysis to quantify cell polarization levels.
Therapeutic efficacy of NZEPTA-Ce against DSS-induced IBD
Establishment and treatment of DSS-induced IBD model
First, IBD was induced by the C57BL/6J mice (male, 8–10 weeks), and the mice were given different group samples to evaluate the therapeutic efficacy of NZEPTA-Ce against IBD. Briefly, the mice were given drinking water containing 3% DSS for 7 days to induce IBD. Then the mice were randomly assigned to five groups (normal, model, YGPs, TA-Ce, and NZEPTA-Ce; n = 5 mice per group). Subsequently, the mice were fed normal drinking water and divided into the following groups for oral administration for 5 days:
(1) Model group (PBS), (2) YGPs group (YGPs dispersed in PBS at a concentration of 87 μg/mL), (3) TA-Ce group (TA-Ce dispersed in PBS at a concentration of 63 μg/mL), (4) NZEPTA-Ce group (NZEPTA-Ce dispersed in PBS at a concentration of 150 μg/mL).
The administration volume for all mice was 0.1 mL/10 g body weight. Meanwhile, mice without any treatment throughout were used as the normal group.
Then the mice were euthanized, and the length of the colon was measured, and the weight of the spleen was measured. Colon tissues were harvested and separated into several sections for further analysis. Moreover, the body weights of all the mice were recorded every 2 days.
Evaluation the potential neuroprotective effects of NZEPTA-Ce in DSS-induced IBD model
Establishment and treatment of DSS-induced IBD
The C57BL/6J mice (male, 8–10 weeks) were given drinking water containing 3% DSS for 7 days to induce IBD. After the model was successfully established, the mice were randomly divided into the following groups for oral administration 5 days:
(1) Model group (PBS), (2) NZEPTA-Ce group (NZEPTA-Ce dispersed in PBS at a concentration of 150 μg/mL). Meanwhile, mice without any treatment throughout were used as the normal group. Afterwards, anxiety and depressive behavioral changes were conducted.
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Supplementary information
References
1.Wehkamp J Gotz M Herrlinger K Steurer W Stange EF Inflammatory bowel disease Dtsch. Arztebl. Int. 2016 113 72 82 26900160 10.3238/arztebl.2016.0072 Wehkamp, J., Gotz, M., Herrlinger, K., Steurer, W. & Stange, E. F. Inflammatory bowel disease. Dtsch. Arztebl. Int.113, 72–82 (2016).10.3238/arztebl.2016.0072 PMC4782273 26900160
2.Baumgart DC Sandborn WJ Crohn’s disease Lancet 2012 380 1590 1605 22914295 10.1016/S0140-6736(12)60026-9 Baumgart, D. C. & Sandborn, W. J. Crohn’s disease. Lancet380, 1590–1605 (2012).10.1016/S0140-6736(12)60026-9 22914295
3.Dubinsky MC Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review Expert Rev. Gastroenterol. Hepatol. 2021 15 985 997 34130572 10.1080/17474124.2021.1911644 Dubinsky, M. C. et al. Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert Rev. Gastroenterol. Hepatol.15, 985–997 (2021).10.1080/17474124.2021.1911644 34130572
4.Barberio B Zamani M Black CJ Savarino EV Ford AC Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis Lancet Gastroenterol. Hepatol. 2021 6 359 370 33721557 10.1016/S2468-1253(21)00014-5 Barberio, B., Zamani, M., Black, C. J., Savarino, E. V. & Ford, A. C. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol.6, 359–370 (2021).10.1016/S2468-1253(21)00014-5 33721557
5.Marrie RA Graff LA Fisk JD Patten SB Bernstein CN The relationship between symptoms of depression and anxiety and disease activity in IBD over time Inflamm. Bowel Dis. 2021 27 1285 1293 33393632 10.1093/ibd/izaa349 Marrie, R. A., Graff, L. A., Fisk, J. D., Patten, S. B. & Bernstein, C. N. The relationship between symptoms of depression and anxiety and disease activity in IBD over time. Inflamm. Bowel Dis.27, 1285–1293 (2021).10.1093/ibd/izaa349 PMC8314114 33393632
6.Nowakowski J Chrobak AA Dudek D Psychiatric illnesses in inflammatory bowel diseases—psychiatric comorbidity and biological underpinnings Psychiatr. Pol. 2016 50 1157 1166 28211554 10.12740/PP/62382 Nowakowski, J., Chrobak, A. A. & Dudek, D. Psychiatric illnesses in inflammatory bowel diseases—psychiatric comorbidity and biological underpinnings. Psychiatr. Pol.50, 1157–1166 (2016).10.12740/PP/62382 28211554
7.Horst S Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease Dig. Dis. Sci. 2015 60 465 470 10.1007/s10620-014-3375-0 25274158 Horst, S. et al. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. Dig. Dis. Sci.60, 465–470 (2015).10.1007/s10620-014-3375-0 25274158
8.Zhang M Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease Patient Prefer. Adherence 2018 12 879 885 29872273 10.2147/PPA.S156883 Zhang, M. et al. Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease. Patient Prefer. Adherence12, 879–885 (2018).10.2147/PPA.S156883 PMC5973631 29872273
9.Carloni S Identification of a choroid plexus vascular barrier closing during intestinal inflammation Science 2021 374 439 448 34672740 10.1126/science.abc6108 Carloni, S. et al. Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science374, 439–448 (2021).10.1126/science.abc6108 34672740
10.Haj-Mirzaian A Anxiety- and depressive-like behaviors are associated with altered hippocampal energy and inflammatory status in a mouse model of Crohn’s disease Neuroscience 2017 366 124 137 29080717 10.1016/j.neuroscience.2017.10.023 Haj-Mirzaian, A. et al. Anxiety- and depressive-like behaviors are associated with altered hippocampal energy and inflammatory status in a mouse model of Crohn’s disease. Neuroscience366, 124–137 (2017).10.1016/j.neuroscience.2017.10.023 29080717
11.Morais LH Schreiber HLT Mazmanian SK The gut microbiota-brain axis in behaviour and brain disorders Nat. Rev. Microbiol. 2021 19 241 255 10.1038/s41579-020-00460-0 33093662 Morais, L. H., Schreiber, H. L. T. & Mazmanian, S. K. The gut microbiota-brain axis in behaviour and brain disorders. Nat. Rev. Microbiol.19, 241–255 (2021).10.1038/s41579-020-00460-0 33093662
12.Collins SM Surette M Bercik P The interplay between the intestinal microbiota and the brain Nat. Rev. Microbiol. 2012 10 735 742 10.1038/nrmicro2876 23000955 Collins, S. M., Surette, M. & Bercik, P. The interplay between the intestinal microbiota and the brain. Nat. Rev. Microbiol.10, 735–742 (2012).10.1038/nrmicro2876 23000955
13.Liu L Gut microbiota and its metabolites in depression: from pathogenesis to treatment EBioMedicine 2023 90 104527 36963238 10.1016/j.ebiom.2023.104527 Liu, L. et al. Gut microbiota and its metabolites in depression: from pathogenesis to treatment. EBioMedicine90, 104527 (2023).10.1016/j.ebiom.2023.104527 PMC10051028 36963238
14.Lee KH Bacterial beta-(1,3)-glucan prevents DSS-induced IBD by restoring the reduced population of regulatory T cells Immunobiology 2014 219 802 812 25092569 10.1016/j.imbio.2014.07.003 Lee, K. H. et al. Bacterial beta-(1,3)-glucan prevents DSS-induced IBD by restoring the reduced population of regulatory T cells. Immunobiology219, 802–812 (2014).10.1016/j.imbio.2014.07.003 25092569
15.Lee C Structural specificities of cell surface beta-glucan polysaccharides determine commensal yeast mediated immuno-modulatory activities Nat. Commun. 2021 12 3611 10.1038/s41467-021-23929-9 34127673 Lee, C. et al. Structural specificities of cell surface beta-glucan polysaccharides determine commensal yeast mediated immuno-modulatory activities. Nat. Commun.12, 3611 (2021).10.1038/s41467-021-23929-9 PMC8203763 34127673
16.Fang Z Evaluation of the antioxidant effects of acid hydrolysates from Auricularia auricular polysaccharides using a Caenorhabditis elegans model Food Funct. 2019 10 5531 5543 31418439 10.1039/C8FO02589D Fang, Z. et al. Evaluation of the antioxidant effects of acid hydrolysates from Auricularia auricular polysaccharides using a Caenorhabditis elegans model. Food Funct.10, 5531–5543 (2019).10.1039/c8fo02589d 31418439
17.Luo X Structural elucidation and immunostimulatory activity of polysaccharide isolated by subcritical water extraction from Cordyceps militaris Carbohydr. Polym. 2017 157 794 802 27987993 10.1016/j.carbpol.2016.10.066 Luo, X. et al. Structural elucidation and immunostimulatory activity of polysaccharide isolated by subcritical water extraction from Cordyceps militaris. Carbohydr. Polym.157, 794–802 (2017).10.1016/j.carbpol.2016.10.066 27987993
18.Nam J Engineered polysaccharides for controlling innate and adaptive immune responses Nat. Rev. Bioeng. 2024 2 733 751 10.1038/s44222-024-00193-2 41059472 Nam, J. et al. Engineered polysaccharides for controlling innate and adaptive immune responses. Nat. Rev. Bioeng.2, 733–751 (2024).10.1038/s44222-024-00193-2 PMC12499632 41059472
19.Yang J Bionic regulators break the ecological niche of pathogenic bacteria for modulating dysregulated microbiome in colitis Adv. Mater. 2022 34 e2204650 35924734 10.1002/adma.202204650 Yang, J. et al. Bionic regulators break the ecological niche of pathogenic bacteria for modulating dysregulated microbiome in colitis. Adv. Mater.34, e2204650 (2022).10.1002/adma.202204650 35924734
20.Cuskin F Human gut Bacteroidetes can utilize yeast mannan through a selfish mechanism Nature 2015 517 165 169 10.1038/nature13995 25567280 Cuskin, F. et al. Human gut Bacteroidetes can utilize yeast mannan through a selfish mechanism. Nature517, 165–169 (2015).10.1038/nature13995 PMC4978465 25567280
21.Jiang D Nanozyme: new horizons for responsive biomedical applications Chem. Soc. Rev. 2019 48 3683 3704 31119258 10.1039/C8CS00718G Jiang, D. et al. Nanozyme: new horizons for responsive biomedical applications. Chem. Soc. Rev.48, 3683–3704 (2019).10.1039/c8cs00718g PMC6696937 31119258
22.Sheng J Multienzyme-like nanozymes: regulation, rational design, and application Adv. Mater. 2024 36 e2211210 36840985 10.1002/adma.202211210 Sheng, J. et al. Multienzyme-like nanozymes: regulation, rational design, and application. Adv. Mater.36, e2211210 (2024).10.1002/adma.202211210 36840985
23.Liu T Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases Nat. Commun. 2020 11 2788 10.1038/s41467-020-16544-7 32493916 Liu, T. et al. Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases. Nat. Commun.11, 2788 (2020).10.1038/s41467-020-16544-7 PMC7270130 32493916
24.Ma L A natural biogenic nanozyme for scavenging superoxide radicals Nat. Commun. 2024 15 233 10.1038/s41467-023-44463-w 38172125 Ma, L. et al. A natural biogenic nanozyme for scavenging superoxide radicals. Nat. Commun.15, 233 (2024).10.1038/s41467-023-44463-w PMC10764798 38172125
25.Zhou X Yeast microcapsule-mediated targeted delivery of diverse nanoparticles for imaging and therapy via the oral route Nano Lett. 2017 17 1056 1064 28075596 10.1021/acs.nanolett.6b04523 Zhou, X. et al. Yeast microcapsule-mediated targeted delivery of diverse nanoparticles for imaging and therapy via the oral route. Nano Lett.17, 1056–1064 (2017).10.1021/acs.nanolett.6b04523 28075596
26.Yang J Cohen Stuart MA Kamperman M Jack of all trades: versatile catechol crosslinking mechanisms Chem. Soc. Rev. 2014 43 8271 8298 25231624 10.1039/C4CS00185K Yang, J., Cohen Stuart, M. A. & Kamperman, M. Jack of all trades: versatile catechol crosslinking mechanisms. Chem. Soc. Rev.43, 8271–8298 (2014).10.1039/c4cs00185k 25231624
27.Yang P Natural polyphenol fluorescent polymer dots Green Chem. 2021 23 1834 1839 10.1039/D0GC02824J Yang, P. et al. Natural polyphenol fluorescent polymer dots. Green Chem.23, 1834–1839 (2021).
28.Wang L Myocardial-targeting tannic cerium nanocatalyst attenuates ischemia/reperfusion injury Angew. Chem. Int. Ed. 2023 62 e202305576 10.1002/anie.202305576 37368480 Wang, L. et al. Myocardial-targeting tannic cerium nanocatalyst attenuates ischemia/reperfusion injury. Angew. Chem. Int. Ed.62, e202305576 (2023).10.1002/anie.202305576 37368480
29.Zhang Q Macroporous array induced multiscale modulation at the surface/interface of Co(OH)2/NiMo self-supporting electrode for effective overall water splitting Adv. Funct. Mater. 2021 31 2102117 10.1002/adfm.202102117 Zhang, Q. et al. Macroporous array induced multiscale modulation at the surface/interface of Co(OH)2/NiMo self-supporting electrode for effective overall water splitting. Adv. Funct. Mater.31, 2102117 (2021).
30.Molano J Bowers B Cabib E Distribution of chitin in the yeast cell wall. An ultrastructural and chemical study J. Cell. Biol. 1980 85 199 212 6989839 10.1083/jcb.85.2.199 Molano, J., Bowers, B. & Cabib, E. Distribution of chitin in the yeast cell wall. An ultrastructural and chemical study. J. Cell. Biol.85, 199–212 (1980).10.1083/jcb.85.2.199 PMC2110607 6989839
31.Fan Y A smart photosensitizer-cerium oxide nanoprobe for highly selective and efficient photodynamic therapy Inorg. Chem. 2019 58 7295 7302 31091081 10.1021/acs.inorgchem.9b00363 Fan, Y. et al. A smart photosensitizer-cerium oxide nanoprobe for highly selective and efficient photodynamic therapy. Inorg. Chem.58, 7295–7302 (2019).10.1021/acs.inorgchem.9b00363 31091081
32.Liu J Mucoadhesive probiotic backpacks with ROS nanoscavengers enhance the bacteriotherapy for inflammatory bowel diseases Sci. Adv. 2022 8 eabp8798 36367930 10.1126/sciadv.abp8798 Liu, J. et al. Mucoadhesive probiotic backpacks with ROS nanoscavengers enhance the bacteriotherapy for inflammatory bowel diseases. Sci. Adv.8, eabp8798 (2022).10.1126/sciadv.abp8798 PMC9651739 36367930
33.Giorgio M Trinei M Migliaccio E Pelicci PG Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat. Rev. Mol. Cell Biol. 2007 8 722 728 10.1038/nrm2240 17700625 Giorgio, M., Trinei, M., Migliaccio, E. & Pelicci, P. G. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat. Rev. Mol. Cell Biol.8, 722–728 (2007).10.1038/nrm2240 17700625
34.Lee Y Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis Nat. Mater. 2020 19 118 126 10.1038/s41563-019-0462-9 31427744 PMC6923573 Lee, Y. et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat. Mater.19, 118–126 (2020).10.1038/s41563-019-0462-9 PMC6923573 31427744
35.Zhong D Orally deliverable strategy based on microalgal biomass for intestinal disease treatment Sci. Adv. 2021 7 eabi9265 34818040 10.1126/sciadv.abi9265 Zhong, D. et al. Orally deliverable strategy based on microalgal biomass for intestinal disease treatment. Sci. Adv.7, eabi9265 (2021).10.1126/sciadv.abi9265 PMC8612690 34818040
36.Fung KY Emerging roles for IL-11 in inflammatory diseases Cytokine 2022 149 155750 34689057 10.1016/j.cyto.2021.155750 Fung, K. Y. et al. Emerging roles for IL-11 in inflammatory diseases. Cytokine149, 155750 (2022).10.1016/j.cyto.2021.155750 34689057
37.Ropeleski MJ Tang J Walsh-Reitz MM Musch MW Chang EB Interleukin-11-induced heat shock protein 25 confers intestinal epithelial-specific cytoprotection from oxidant stress Gastroenterology 2003 124 1358 1368 12730876 10.1016/S0016-5085(03)00282-8 Ropeleski, M. J., Tang, J., Walsh-Reitz, M. M., Musch, M. W. & Chang, E. B. Interleukin-11-induced heat shock protein 25 confers intestinal epithelial-specific cytoprotection from oxidant stress. Gastroenterology124, 1358–1368 (2003).10.1016/s0016-5085(03)00282-8 12730876
38.Tilg H Moschen AR IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation J. Hepatol. 2011 55 960 962 21742000 10.1016/j.jhep.2011.04.007 Tilg, H. & Moschen, A. R. IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. J. Hepatol.55, 960–962 (2011).10.1016/j.jhep.2011.04.007 21742000
39.Wang Q Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages Cell Res. 2010 20 701 712 10.1038/cr.2010.52 20386569 Wang, Q. et al. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res.20, 701–712 (2010).10.1038/cr.2010.52 20386569
40.Neurath MF Strategies for targeting cytokines in inflammatory bowel disease Nat. Rev. Immunol. 2024 24 559 576 10.1038/s41577-024-01008-6 38486124 Neurath, M. F. Strategies for targeting cytokines in inflammatory bowel disease. Nat. Rev. Immunol.24, 559–576 (2024).10.1038/s41577-024-01008-6 38486124
41.Min DK Orally administrated inflamed colon-targeted nanotherapeutics for inflammatory bowel disease treatment by oxidative stress level modulation in colitis ACS Nano 2023 17 24404 24416 38039189 10.1021/acsnano.3c11089 Min, D. K. et al. Orally administrated inflamed colon-targeted nanotherapeutics for inflammatory bowel disease treatment by oxidative stress level modulation in colitis. ACS Nano17, 24404–24416 (2023).10.1021/acsnano.3c11089 38039189
42.D’Alessio S Revisiting fibrosis in inflammatory bowel disease: the gut thickens Nat. Rev. Gastroenterol. Hepatol. 2022 19 169 184 10.1038/s41575-021-00543-0 34876680 D’Alessio, S. et al. Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat. Rev. Gastroenterol. Hepatol.19, 169–184 (2022).10.1038/s41575-021-00543-0 34876680
43.Schluter J The gut microbiota is associated with immune cell dynamics in humans Nature 2020 588 303 307 10.1038/s41586-020-2971-8 33239790 Schluter, J. et al. The gut microbiota is associated with immune cell dynamics in humans. Nature588, 303–307 (2020).10.1038/s41586-020-2971-8 PMC7725892 33239790
44.Al-Amrah H Composition of the gut microbiota in patients with inflammatory bowel disease in Saudi Arabia: a pilot study Saudi J. Gastroenterol. 2023 29 102 110 36695274 10.4103/sjg.sjg_368_22 Al-Amrah, H. et al. Composition of the gut microbiota in patients with inflammatory bowel disease in Saudi Arabia: a pilot study. Saudi J. Gastroenterol.29, 102–110 (2023).10.4103/sjg.sjg_368_22 PMC10270479 36695274
45.Zhang L The norepinephrine-QseC axis aggravates F. nucleatum-associated colitis through interkingdom signaling Inflamm. Bowel Dis. 2024 30 2127 2135 38552106 10.1093/ibd/izae063 Zhang, L. et al. The norepinephrine-QseC axis aggravates F. nucleatum-associated colitis through interkingdom signaling. Inflamm. Bowel Dis.30, 2127–2135 (2024).10.1093/ibd/izae063 38552106
46.Qiu X Zhang M Yang X Hong N Yu C Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis J. Crohns Colitis 2013 7 e558 e568 23643066 10.1016/j.crohns.2013.04.002 Qiu, X., Zhang, M., Yang, X., Hong, N. & Yu, C. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J. Crohns Colitis7, e558–e568 (2013).10.1016/j.crohns.2013.04.002 23643066
47.Guo, C. et al. Chitosan oligosaccharides alleviate colitis by regulating intestinal microbiota and PPARgamma/SIRT1-mediated NF-kappaB pathway. Mar. Drugs. 20, 96 (2022).10.3390/md20020096 PMC8880253 35200626
48.Chen MM Young adults with major depression show altered microbiome Neuroscience 2023 522 23 32 37169166 10.1016/j.neuroscience.2023.05.002 Chen, M. M. et al. Young adults with major depression show altered microbiome. Neuroscience522, 23–32 (2023).10.1016/j.neuroscience.2023.05.002 37169166
49.Hu X Changes of gut microbiota reflect the severity of major depressive disorder: a cross sectional study Transl. Psychiatry 2023 13 137 10.1038/s41398-023-02436-z 37117202 Hu, X. et al. Changes of gut microbiota reflect the severity of major depressive disorder: a cross sectional study. Transl. Psychiatry13, 137 (2023).10.1038/s41398-023-02436-z PMC10147706 37117202
50.Chang et al. The metabolomics analysis of cecal contents elucidates significant metabolites involved in the therapeutic effects of total flavonoids derived from Sonchus arvensis L. in male C57BL/6 mice with ulcerative colitis. Heliyon10, e32790 (2024).10.1016/j.heliyon.2024.e32790 PMC11239596 39005925
51.Zhao R Mineralocorticoid promotes intestinal inflammation through receptor dependent IL17 production in ILC3s Int. Immunopharmacol. 2024 130 111678 38368773 10.1016/j.intimp.2024.111678 Zhao, R. et al. Mineralocorticoid promotes intestinal inflammation through receptor dependent IL17 production in ILC3s. Int. Immunopharmacol.130, 111678 (2024).10.1016/j.intimp.2024.111678 38368773
52.Emanuele E Geroldi D Minoretti P Coen E Politi P Increased plasma aldosterone in patients with clinical depression Arch. Med. Res. 2005 36 544 548 16099336 10.1016/j.arcmed.2005.03.046 Emanuele, E., Geroldi, D., Minoretti, P., Coen, E. & Politi, P. Increased plasma aldosterone in patients with clinical depression. Arch. Med. Res.36, 544–548 (2005).10.1016/j.arcmed.2005.03.046 16099336
53.Hlavacova N Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder Int. J. Neuropsychopharmacol. 2012 15 247 265 21375792 10.1017/S1461145711000368 Hlavacova, N. et al. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int. J. Neuropsychopharmacol.15, 247–265 (2012).10.1017/S1461145711000368 21375792
54.Zhang J Distinct differences in serum eicosanoids in healthy, enteritis and colorectal cancer individuals Metabolomics 2017 14 4 10.1007/s11306-017-1293-9 30830334 Zhang, J. et al. Distinct differences in serum eicosanoids in healthy, enteritis and colorectal cancer individuals. Metabolomics14, 4 (2017).10.1007/s11306-017-1293-9 30830334
55.Lucchinetti E Novel lipid emulsion for total parenteral nutrition based on 18-carbon n-3 fatty acids elicits a superior immunometabolic phenotype in a murine model compared with standard lipid emulsions Am. J. Clin. Nutr. 2022 116 1805 1819 36166844 10.1093/ajcn/nqac272 Lucchinetti, E. et al. Novel lipid emulsion for total parenteral nutrition based on 18-carbon n-3 fatty acids elicits a superior immunometabolic phenotype in a murine model compared with standard lipid emulsions. Am. J. Clin. Nutr.116, 1805–1819 (2022).10.1093/ajcn/nqac272 36166844
56.Pauls SD Anti-inflammatory effects of alpha-linolenic acid in M1-like macrophages are associated with enhanced production of oxylipins from alpha-linolenic and linoleic acid J. Nutr. Biochem. 2018 57 121 129 29698923 10.1016/j.jnutbio.2018.03.020 Pauls, S. D. et al. Anti-inflammatory effects of alpha-linolenic acid in M1-like macrophages are associated with enhanced production of oxylipins from alpha-linolenic and linoleic acid. J. Nutr. Biochem.57, 121–129 (2018).10.1016/j.jnutbio.2018.03.020 29698923
57.Dignass AU Baumgart DC Sturm A Review article: the aetiopathogenesis of inflammatory bowel disease-immunology and repair mechanisms Aliment. Pharmacol. Ther. 2004 20 9 17 15352888 10.1111/j.1365-2036.2004.02047.x Dignass, A. U., Baumgart, D. C. & Sturm, A. Review article: the aetiopathogenesis of inflammatory bowel disease-immunology and repair mechanisms. Aliment. Pharmacol. Ther.20, 9–17 (2004).10.1111/j.1365-2036.2004.02047.x 15352888
58.Whelan J Dietary stearidonic acid is a long chain (n-3) polyunsaturated fatty acid with potential health benefits J. Nutr. 2009 139 5 10 19056654 10.3945/jn.108.094268 Whelan, J. Dietary stearidonic acid is a long chain (n-3) polyunsaturated fatty acid with potential health benefits. J. Nutr.139, 5–10 (2009).10.3945/jn.108.094268 19056654
59.Li, Y. et al. Neuroprotective effect of stearidonic acid on amyloid beta-induced neurotoxicity in rat hippocampal cells. Antioxidants11, 2357 (2022).10.3390/antiox11122357 PMC9774633 36552565
60.Yao T Metabolomic evidence for the therapeutic effect of gentiopicroside in a corticosterone-induced model of depression Biomed. Pharmacother. 2019 120 109549 31655313 10.1016/j.biopha.2019.109549 Yao, T. et al. Metabolomic evidence for the therapeutic effect of gentiopicroside in a corticosterone-induced model of depression. Biomed. Pharmacother.120, 109549 (2019).10.1016/j.biopha.2019.109549 31655313
61.Li M Transcriptome profiles of corticosterone-induced cytotoxicity reveals the involvement of neurite growth-related genes in depression Psychiatry Res. 2019 276 79 86 31029038 10.1016/j.psychres.2019.04.017 Li, M. et al. Transcriptome profiles of corticosterone-induced cytotoxicity reveals the involvement of neurite growth-related genes in depression. Psychiatry Res.276, 79–86 (2019).10.1016/j.psychres.2019.04.017 31029038
62.Schumacher S Laufer S Fischer S Fingernail cortisol: a biological signal of lifetime major depressive disorder Neuropsychobiology 2023 82 300 305 37806304 10.1159/000531315 Schumacher, S., Laufer, S. & Fischer, S. Fingernail cortisol: a biological signal of lifetime major depressive disorder. Neuropsychobiology82, 300–305 (2023).10.1159/000531315 PMC10614476 37806304
63.Sakhaee E The role of NMDA receptor and nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effect of dextromethorphan in mice forced swimming test and tail suspension test Biomed. Pharmacother. 2017 85 627 634 27908707 10.1016/j.biopha.2016.11.073 Sakhaee, E. et al. The role of NMDA receptor and nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effect of dextromethorphan in mice forced swimming test and tail suspension test. Biomed. Pharmacother.85, 627–634 (2017).10.1016/j.biopha.2016.11.073 27908707
64.Tan YF Liao ZL Qiu YJ Zhu JP Yu EY Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant-like effect of Wuling mycelia powder in rat Biomed. Pharmacother. 2016 78 60 65 26898425 10.1016/j.biopha.2015.12.016 Tan, Y. F., Liao, Z. L., Qiu, Y. J., Zhu, J. P. & Yu, E. Y. Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant-like effect of Wuling mycelia powder in rat. Biomed. Pharmacother.78, 60–65 (2016).10.1016/j.biopha.2015.12.016 26898425
65.Prut L Belzung C The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review Eur. J. Pharmacol. 2003 463 3 33 12600700 10.1016/S0014-2999(03)01272-X Prut, L. & Belzung, C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol.463, 3–33 (2003).10.1016/s0014-2999(03)01272-x 12600700
66.Shi Y P2-123: the candidate therapeutic target in a rat model of depression Alzheimer's Dement. 2016 12 P659-P659 10.1016/j.jalz.2016.06.1493 Shi, Y. P2-123: the candidate therapeutic target in a rat model of depression. Alzheimer's Dement.12, P659-P659 (2016).
Come citare questo studio
Zhang F, Chen L, Wang S, Chen X, Du K, Song F, Jiang L, Feng Y, Du S, Jiang T, Liu Y, Xiao J. (2026). Bioinspired nanozyme-exoskeletonized yeast-derived polysaccharides for treating comorbid anxiety and depression in inflammatory bowel disease.. Nature communications. DOI: 10.1038/s41467-026-78633-3
Consulta la pubblicazione originale ↗